加载中
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.
常规交易时段
US$13.965
−US$0.305 · -2.14%
盘中时间采用ET。市场数据可能有所延迟。
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.
日内区间
当前US$13.965
52周区间
当前US$13.965
盘中时间采用ET。市场数据可能有所延迟。
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.
日内区间
当前US$13.965
52周区间
当前US$13.965
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 1.21亿 USD | 1719.8万 USD | 590.2万 USD | 750.1万 USD | 1021.1万 USD |
| 销货成本 | 1921.14万 USD | 513万 USD | 4107万 USD | 5492.2万 USD | 6357.2万 USD |
| 毛利 | 1.02亿 USD | 1206.8万 USD | −3516.8万 USD | −4742.1万 USD | −5336.1万 USD |
| 研究与开发 | 9794.46万 USD | 3480.7万 USD | 2535.3万 USD | 2718.9万 USD | 3281.5万 USD |
| 销售、一般及管理费用 | 5513.22万 USD | 3930.9万 USD | 2362.6万 USD | 5310.7万 USD | 5796.7万 USD |
| 营业费用 | 1.53亿 USD | 7451.1万 USD | 4897.9万 USD | 7679万 USD | 9078.5万 USD |
| 利息收入 | 393.15万 USD | 355.4万 USD | 182.4万 USD | 83.1万 USD | — |
| 利息支出 | 2394.55万 USD | 2292.9万 USD | 2065.8万 USD | 1944.4万 USD | 1728.8万 USD |
| 折旧和摊销 | 862.34万 USD | 640万 USD | 466.6万 USD | 410.7万 USD | 438万 USD |
| 营业利润 | −5150.1万 USD | −6244.3万 USD | −8414.7万 USD | −6928.9万 USD | −8057.4万 USD |
| 净利润 | −5775.69万 USD | −1.02亿 USD | −8795.6万 USD | −8188.9万 USD | −9134.7万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$39.00
上涨空间 179.27%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2024年1月10日 | 1:2 | — | — |
股票拆分 | 2023年12月5日 | 529:500 | — | — |
股票拆分 | 2017年8月29日 | 1,011:1,000 | — | — |
已生效 2024年1月10日
1:2
已生效 2023年12月5日
529:500
已生效 2017年8月29日
1,011:1,000
报告持有此股票敞口的交易所交易基金。
iShares Biotechnology ETFIBB817.77万0.08%108.2亿 USD0.44%US$201.49-1.36%
ActivePassive International Equity ETFAPIE16.38万0.01%11.36亿 USD0.45%US$38.4679+0.18%
Invesco NASDAQ Future Gen 200 ETFQQQS10.23万0.45%2275.83万 USD0.20%US$40.735-1.64%
Invesco Nasdaq Biotechnology ETFIBBQ5.62万0.05%1.12亿 USD0.19%US$33.73-1.51%
ProShares Ultra Nasdaq BiotechnologyBIB2.87万0.03%9138.97万 USD1.19%US$105.49-3.03%iShares Biotechnology ETFIBBActivePassive International Equity ETFAPIEInvesco NASDAQ Future Gen 200 ETFQQQSInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
